{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:53:37Z","timestamp":1782363217068,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["K12AR084231"],"award-info":[{"award-number":["K12AR084231"]}]},{"name":"NIH","award":["P30CA014236"],"award-info":[{"award-number":["P30CA014236"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18307-4","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:18:11Z","timestamp":1758385091000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic"],"prefix":"10.1245","volume":"33","author":[{"given":"Sasha R.","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Botty","family":"van den Bruele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra M.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Rosenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie L.","family":"DiNome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"issue":"11","key":"18307_CR1","first-page":"1440","volume":"107","author":"CO Collaborative","year":"2020","unstructured":"Collaborative CO. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107(11):1440\u20139.","journal-title":"Br J Surg"},{"issue":"3","key":"18307_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","volume":"181","author":"JR Dietz","year":"2020","unstructured":"Dietz JR, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020;181(3):487\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"18307_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485\u2013505.","journal-title":"J Clin Oncol"},{"issue":"5","key":"18307_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2009.01.035","volume":"208","author":"JA Olson Jr","year":"2009","unstructured":"Olson JA Jr, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009;208(5):906\u201314.","journal-title":"J Am Coll Surg"},{"issue":"10","key":"18307_CR5","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1245\/s10434-021-10459-3","volume":"28","author":"L Cao","year":"2021","unstructured":"Cao L, et al. Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes. Ann Surg Oncol. 2021;28(10):5730\u201341.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"18307_CR6","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-022-12972-5","volume":"30","author":"KK Hunt","year":"2023","unstructured":"Hunt KK, et al. Local-regional recurrence after neoadjuvant endocrine therapy: data from ACOSOG Z1031 (Alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer. Ann Surg Oncol. 2023;30(4):2111\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"18307_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XCS.0000000000001214","volume":"240","author":"EB Habermann","year":"2025","unstructured":"Habermann EB, et al. American college of surgeons cancer program annual report from 2021 participant user file. J Am Coll Surg. 2025;240(1):95\u2013110.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"18307_CR8","doi-asserted-by":"publisher","first-page":"e35525","DOI":"10.1002\/cncr.35525","volume":"131","author":"JK Plichta","year":"2025","unstructured":"Plichta JK, et al. Comparison of incident breast cancer cases in the largest national US tumor registries. Cancer. 2025;131(1):e35525.","journal-title":"Cancer"},{"issue":"11","key":"18307_CR9","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.1245\/s10434-024-15787-8","volume":"31","author":"R Khorfan","year":"2024","unstructured":"Khorfan R, et al. Expanded indications for neoadjuvant endocrine therapy in early-stage breast cancer during the COVID-19 pandemic. Ann Surg Oncol. 2024;31(11):7562\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"18307_CR10","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1245\/s10434-020-08888-7","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, et al. How Effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery? Ann Surg Oncol. 2020;27(12):4702\u201310.","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"18307_CR11","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"18307_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1245\/s10434-016-5585-5","volume":"24","author":"A Chiba","year":"2017","unstructured":"Chiba A, et al. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer database study. Ann Surg Oncol. 2017;24(2):418\u201324.","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"18307_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"18307_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"18307_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-023-06874-7","volume":"199","author":"H Iwata","year":"2023","unstructured":"Iwata H, et al. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with\/without adjuvant chemotherapy. Breast Cancer Res Treat. 2023;199(2):231\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"18307_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-025-07717-3","volume":"212","author":"TC Nierenberg","year":"2025","unstructured":"Nierenberg TC, et al. Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs neoadjuvant chemotherapy: a retrospective national database study. Breast Cancer Res Treat. 2025;212(1):161\u201372.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18307-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18307-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18307-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:05Z","timestamp":1765289345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18307-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18307"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18307-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}